An overview on severe acute respiratory syndrome (SARS).
Identifieur interne : 001286 ( Ncbi/Merge ); précédent : 001285; suivant : 001287An overview on severe acute respiratory syndrome (SARS).
Auteurs : D S C. Hui [Hong Kong]Source :
- Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace [ 1122-0643 ] ; 2005.
Descripteurs français
- KwdFr :
- ARN viral (analyse), Antiviraux (usage thérapeutique), Coronavirus (génétique), Humains, Incidence, Indice de gravité médicale, Oxygénothérapie, Santé mondiale, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (épidémiologie), Taux de survie (tendances), Ventilation artificielle.
- MESH :
- analyse : ARN viral.
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Coronavirus.
- tendances : Taux de survie.
- usage thérapeutique : Antiviraux.
- épidémiologie : Syndrome respiratoire aigu sévère.
- Humains, Incidence, Indice de gravité médicale, Oxygénothérapie, Santé mondiale, Syndrome respiratoire aigu sévère, Ventilation artificielle.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Coronavirus (genetics), Global Health, Humans, Incidence, Oxygen Inhalation Therapy, RNA, Viral (analysis), Respiration, Artificial, Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (therapy), Severity of Illness Index, Survival Rate (trends).
- MESH :
- chemical , analysis : RNA, Viral.
- chemical , therapeutic use : Antiviral Agents.
- diagnosis : Severe Acute Respiratory Syndrome.
- epidemiology : Severe Acute Respiratory Syndrome.
- genetics : Coronavirus.
- therapy : Severe Acute Respiratory Syndrome.
- trends : Survival Rate.
- Global Health, Humans, Incidence, Oxygen Inhalation Therapy, Respiration, Artificial, Severity of Illness Index.
Abstract
Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease that has caught the medical profession by surprise in 2003. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea but diarrhea occurs in 40-70% of patients after hospital admission. Respiratory failure is the major complication of SARS; at least half of the patients require supplemental oxygen during the acute phase whereas about 20% of patients progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. In contrast, the severity is generally mild in infected young children. Due to our limited understanding of this new disease, treatment of SARS was empirical in 2003. Protease inhibitor (Lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase whereas nelfinavir is a promising alternative. The role of interferon and systemic steroid in preventing immune-mediated lung injury deserves further investigation. In addition, other anti-viral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. Rapid diagnosis, early isolation, and good infection control measures are important in preventing spread of the infection.
DOI: 10.4081/monaldi.2005.632
PubMed: 16312205
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002426
- to stream PubMed, to step Curation: 002426
- to stream PubMed, to step Checkpoint: 002834
Links to Exploration step
pubmed:16312205Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An overview on severe acute respiratory syndrome (SARS).</title><author><name sortKey="Hui, D S C" sort="Hui, D S C" uniqKey="Hui D" first="D S C" last="Hui">D S C. Hui</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong. dschui@cuhk.edu.hk</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16312205</idno><idno type="pmid">16312205</idno><idno type="doi">10.4081/monaldi.2005.632</idno><idno type="wicri:Area/PubMed/Corpus">002426</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002426</idno><idno type="wicri:Area/PubMed/Curation">002426</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002426</idno><idno type="wicri:Area/PubMed/Checkpoint">002834</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002834</idno><idno type="wicri:Area/Ncbi/Merge">001286</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">An overview on severe acute respiratory syndrome (SARS).</title><author><name sortKey="Hui, D S C" sort="Hui, D S C" uniqKey="Hui D" first="D S C" last="Hui">D S C. Hui</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong. dschui@cuhk.edu.hk</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author></analytic><series><title level="j">Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</title><idno type="ISSN">1122-0643</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus (genetics)</term><term>Global Health</term><term>Humans</term><term>Incidence</term><term>Oxygen Inhalation Therapy</term><term>RNA, Viral (analysis)</term><term>Respiration, Artificial</term><term>Severe Acute Respiratory Syndrome (diagnosis)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Severity of Illness Index</term><term>Survival Rate (trends)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (analyse)</term><term>Antiviraux (usage thérapeutique)</term><term>Coronavirus (génétique)</term><term>Humains</term><term>Incidence</term><term>Indice de gravité médicale</term><term>Oxygénothérapie</term><term>Santé mondiale</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (diagnostic)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Taux de survie (tendances)</term><term>Ventilation artificielle</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Taux de survie</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Survival Rate</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Global Health</term><term>Humans</term><term>Incidence</term><term>Oxygen Inhalation Therapy</term><term>Respiration, Artificial</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Incidence</term><term>Indice de gravité médicale</term><term>Oxygénothérapie</term><term>Santé mondiale</term><term>Syndrome respiratoire aigu sévère</term><term>Ventilation artificielle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease that has caught the medical profession by surprise in 2003. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea but diarrhea occurs in 40-70% of patients after hospital admission. Respiratory failure is the major complication of SARS; at least half of the patients require supplemental oxygen during the acute phase whereas about 20% of patients progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. In contrast, the severity is generally mild in infected young children. Due to our limited understanding of this new disease, treatment of SARS was empirical in 2003. Protease inhibitor (Lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase whereas nelfinavir is a promising alternative. The role of interferon and systemic steroid in preventing immune-mediated lung injury deserves further investigation. In addition, other anti-viral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. Rapid diagnosis, early isolation, and good infection control measures are important in preventing spread of the infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16312205</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1122-0643</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</Title><ISOAbbreviation>Monaldi Arch Chest Dis</ISOAbbreviation></Journal><ArticleTitle>An overview on severe acute respiratory syndrome (SARS).</ArticleTitle><Pagination><MedlinePgn>149-57</MedlinePgn></Pagination><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease that has caught the medical profession by surprise in 2003. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea but diarrhea occurs in 40-70% of patients after hospital admission. Respiratory failure is the major complication of SARS; at least half of the patients require supplemental oxygen during the acute phase whereas about 20% of patients progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. In contrast, the severity is generally mild in infected young children. Due to our limited understanding of this new disease, treatment of SARS was empirical in 2003. Protease inhibitor (Lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase whereas nelfinavir is a promising alternative. The role of interferon and systemic steroid in preventing immune-mediated lung injury deserves further investigation. In addition, other anti-viral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. Rapid diagnosis, early isolation, and good infection control measures are important in preventing spread of the infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>D S C</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong. dschui@cuhk.edu.hk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Monaldi Arch Chest Dis</MedlineTA><NlmUniqueID>9307314</NlmUniqueID><ISSNLinking>1122-0643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="Y">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>120</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16312205</ArticleId><ArticleId IdType="doi">10.4081/monaldi.2005.632</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Hong Kong</li></country><settlement><li>Sha Tin</li></settlement><orgName><li>Université chinoise de Hong Kong</li></orgName></list><tree><country name="Hong Kong"><noRegion><name sortKey="Hui, D S C" sort="Hui, D S C" uniqKey="Hui D" first="D S C" last="Hui">D S C. Hui</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001286 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001286 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16312205
|texte= An overview on severe acute respiratory syndrome (SARS).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16312205" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |